Literature DB >> 24684706

Secondary antibody deficiency.

Sai S Duraisingham1, Matthew S Buckland, Sofia Grigoriadou, Hilary J Longhurst.   

Abstract

Secondary antibody deficiencies are defined by a quantitative or qualitative decrease in antibodies that occur most commonly as a consequence of renal or gastrointestinal immunoglobulin loss, hematological malignancies and corticosteroid, immunosuppressive or anticonvulsant medications. Patients with hematological malignancies or requiring immunosuppressive medications are known to be at increased risk of infection, but few studies directly address this relationship in the context of antibody deficiency. Immunoglobulin replacement therapy has been shown to be effective in reducing infections in primary and some secondary antibody deficiencies. The commonly encountered causes of secondary antibody deficiencies and their association with infection-related morbidity and mortality are discussed. Recommendations are made for screening and clinical management of those at risk.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24684706     DOI: 10.1586/1744666X.2014.902314

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  13 in total

Review 1.  When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.

Authors:  S Jolles; H Chapel; J Litzman
Journal:  Clin Exp Immunol       Date:  2017-01-30       Impact factor: 4.330

Review 2.  Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.

Authors:  Jacqueline Kerr; Isabella Quinti; Martha Eibl; Helen Chapel; Peter J Späth; W A Carrock Sewell; Abdulgabar Salama; Ivo N van Schaik; Taco W Kuijpers; Hans-Hartmut Peter
Journal:  Front Immunol       Date:  2014-12-12       Impact factor: 7.561

Review 3.  The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.

Authors:  Smita Y Patel; Javier Carbone; Stephen Jolles
Journal:  Front Immunol       Date:  2019-02-08       Impact factor: 7.561

4.  Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases.

Authors:  Sonali Wijetilleka; David Jayne; Chetan Mukhtyar; Mohammed Yousuf Karim
Journal:  Lupus Sci Med       Date:  2019-07-30

5.  Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement.

Authors:  Sai S Duraisingham; Matthew Buckland; John Dempster; Lorena Lorenzo; Sofia Grigoriadou; Hilary J Longhurst
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

Review 6.  Comparison of diagnostic criteria for common variable immunodeficiency disorder.

Authors:  Rohan Ameratunga; Maia Brewerton; Charlotte Slade; Anthony Jordan; David Gillis; Richard Steele; Wikke Koopmans; See-Tarn Woon
Journal:  Front Immunol       Date:  2014-09-15       Impact factor: 7.561

Review 7.  Primary immunodeficiency.

Authors:  Christine McCusker; Julia Upton; Richard Warrington
Journal:  Allergy Asthma Clin Immunol       Date:  2018-09-12       Impact factor: 3.406

8.  The Natural History of Untreated Primary Hypogammaglobulinemia in Adults: Implications for the Diagnosis and Treatment of Common Variable Immunodeficiency Disorders (CVID).

Authors:  Rohan Ameratunga; Yeri Ahn; Richard Steele; See-Tarn Woon
Journal:  Front Immunol       Date:  2019-07-17       Impact factor: 7.561

9.  The critical role of histology in distinguishing sarcoidosis from common variable immunodeficiency disorder (CVID) in a patient with hypogammaglobulinemia.

Authors:  Rohan Ameratunga; Yeri Ahn; Dominic Tse; See-Tarn Woon; Jennifer Pereira; Sinead McCarthy; Hilary Blacklock
Journal:  Allergy Asthma Clin Immunol       Date:  2019-12-02       Impact factor: 3.406

10.  All Patients With Common Variable Immunodeficiency Disorders (CVID) Should Be Routinely Offered Diagnostic Genetic Testing.

Authors:  Rohan Ameratunga; Klaus Lehnert; See-Tarn Woon
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.